|
| Screening purpose | Cell type | Strain | Genes identified | Reference |
|
Loss of function | | | | | |
Drug resistance | 6-thioguanine | Blm-deficient ESCs | Mouse | Dnmt1 | Guo et al., 2004 (ref [96]) |
6-thioguanine | haESCs | Mouse | Msh2, Hprt | Leeb et al., 2011 (ref [100]) |
6-thioguanine | haESCs | Mouse | Mismatch repair genes (Msh2, Msh6, Mlh1) | Pettitt et al., 2013 (ref [124]) |
Olaparib (PARP inhibitor) | haESCs | Mouse | Parp1 | Pettitt et al., 2013 (ref [124]) |
Talazoparib (PARP inhibitor) | haESCs | Mouse | Ewsr1 | Pettitt et al., 2017 (ref [113]) |
Doxorubicin | haESCs | Mouse | Rmi2,Pdk4, and Acbd6 | Liu et al., 2017 (ref [91]) |
Tetrodotoxin-like toxicant | haNPCs | Rhesus monkey | B4GALT6 | Wang et al., 2018 (ref [38]) |
6-thioguanine | haTSCs | Mouse | Hprt | Cui et al., 2019 (ref [155]) |
Puromycin | haESCs | Mouse | Lrp6 | Mao et al., 2020 (ref [126]) |
Stem cell-related characteristics | Exit from self-renewal | haESCs | Mouse | Zfp706, Pum1 | Leeb et al., 2014 (ref [108]) |
Exit-from-pluripotency | haESCs | Mouse | Garnl3, Ifltd1, Sema5a, Cdk5rap2 and Phf21a | Liu et al., 2017 (ref [91]) |
Spongiotrophoblast specification | haiTSCs | Mouse | Htra1 | Peng et al., 2019 (ref [118]) |
Reprogramming factors | haEpiSCs | Mouse | Hs3st3b1 | Gao et al., 2021 (ref [122]) |
Haploidy maintenance | haESCs | Mouse | Etl4 | Zhang et al., 2020 (ref [123]) |
Gain of function | | | | | |
Drug resistance | PluriSIn-1(SCD1 inhibitor) | ESC | Human | RAS pathway genes | Weissbein et al., [2019] (ref [127]) |
Stem cell-related characteristics | Ground state pluripotency | EpiSCs | Mouse | Nr5a | Guo et al., 2010 (ref [35]) |
Cell differentiation | ESC | Human | RHOA | Gayle et al., 2015 (ref [156]) |
Growth advantage | ESC | Human | RHO-ROCK pathway genes | Weissbein et al., 2019 (ref [127]) |
Teratoma formation | ESC | Human | PI3K-AKT and HIPPO pathways genes | Weissbein et al., 2019 (ref [127]) |
|